Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence

International Journal of Cancer. Journal International Du Cancer
Caroline L SmithVincenzo Cerundolo

Abstract

Recombinant plasmid DNA and attenuated poxviruses are under development as cancer and infectious disease vaccines. We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes. HLA-A*0201-positive patients with surgically treated melanoma received either a "prime-boost" DNA/MVA or a homologous MVA-only regimen. Ex vivo tetramer analysis, performed at multiple time points, provided detailed kinetics of vaccine-driven CTL responses specific for the high-affinity melan-A(26-35) analogue epitope. Melan-A26-35-specific CTL were generated in 2/6 patients who received DNA/MVA (detectable only after the first MVA injection) and 4/7 patients who received MVA only. Ex vivo ELISPOT analysis and in vitro proliferation assays confirmed the effector function of these CTL. Responses were seen in smallpox-vaccinated as well as vaccinia-naive patients, as defined by anti-vaccinia antibody responses demonstrated by ELISA assay. The observations that 1) CTL responses were generated to only 1 of the recombinant epitopes and 2) that the magnitude of these responses (0.029-0.19% CD8(+) T cells) was below the levels usuall...Continue Reading

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G Sutter, B Moss
Oct 4, 1996·Science·J D AltmanM M Davis
Jan 1, 1997·Annual Review of Immunology·J J DonnellyM A Liu
Mar 31, 2000·Immunology Today·I A Ramshaw, A J Ramsay
Sep 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·B Schuler-ThurnerG Schuler
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·E JägerA Knuth
Oct 18, 2000·The Journal of Experimental Medicine·R M KedlP Marrack
Nov 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·P R DunbarV Cerundolo
Dec 29, 2000·Nature·H HemmiS Akira
Apr 3, 2001·Science·D Paydarfar, W J Schwartz
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M SalioV Cerundolo
Mar 30, 2002·The New England Journal of Medicine·Sharon E FreyFrancis A Ennis
Apr 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael J PalmowskiVincenzo Cerundolo
May 11, 2002·Nature Reviews. Immunology·Paul KlenermanP Rod Dunbar
Jul 23, 2002·Trends in Immunology·Michael Rehli
Aug 7, 2002·The Journal of Clinical Investigation·Zhiya Yu, Nicholas P Restifo
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John W SmithWalter J Urba
Jun 26, 2003·JAMA : the Journal of the American Medical Association·Sharon E FreyRobert B Belshe
Aug 20, 2003·Nature Medicine·Erika HammarlundMark K Slifka
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Edwin B WalkerWalter J Urba

❮ Previous
Next ❯

Citations

Mar 1, 2006·Cancer Immunology, Immunotherapy : CII·A G Dalgleish, M A Whelan
Jan 1, 2010·Cancer Immunology, Immunotherapy : CII·Adam DangoorRobert Hawkins
Apr 6, 2011·Cancer Immunology, Immunotherapy : CII·Jianda YuanJedd D Wolchok
Oct 8, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elodie BelnoueMireille Viguier
Jan 26, 2008·Nature Reviews. Cancer·Jason RiceFreda K Stevenson
Dec 17, 2008·Nature Reviews. Immunology·Vincenzo CerundoloMariolina Salio
Sep 9, 2009·Pigment Cell & Melanoma Research·Camilla JandusPedro Romero
Mar 23, 2006·Annual Review of Immunology·Thierry BoonPierre van der Bruggen
Jul 10, 2010·Journal of Biomedicine & Biotechnology·Roberto Bei, Antonio Scardino
May 24, 2011·PloS One·Richard HopkinsTomáš Hanke
Nov 19, 2009·Cancer Immunology, Immunotherapy : CII·W ZhangE J Usherwood
Aug 23, 2011·Expert Review of Vaccines·Stephen R Walsh, Raphael Dolin
Apr 26, 2006·Expert Opinion on Emerging Drugs·Helen Fletcher, Helen McShane
Jun 7, 2005·Expert Opinion on Biological Therapy·L G Durrant, J M Ramage
Apr 7, 2010·Journal of Biomedicine & Biotechnology·Daniela FiorettiMonica Rinaldi
Aug 19, 2007·Vaccine·Richard J Anderson, Joerg Schneider
Jun 10, 2006·Hematology/oncology Clinics of North America·Rodica StanAdam D Cohen
Aug 23, 2005·International Journal of Cancer. Journal International Du Cancer·Kamel Ait-TaharKaren Pulford
Apr 28, 2007·Immunology·Arturo Reyes-SandovalStephen M Todryk
Sep 19, 2006·Advanced Drug Delivery Reviews·Z Tabi, S Man
Aug 27, 2005·Expert Opinion on Biological Therapy·Michel AdaminaPaul Zajac
Jun 5, 2013·Oncoimmunology·Laura SenovillaLorenzo Galluzzi
Jun 19, 2009·Immunome Research·Maya F KotturiAlessandro Sette

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.